OTCMKTS:COTQF - Cotinga Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.0829 0.00 (0.00 %) (As of 05/19/2019 04:00 PM ET)Previous Close$0.0829Today's Range$0.0829 - $0.083952-Week Range$0.01 - $1.40Volume348 shsAverage Volume2,142 shsMarket Capitalization$1.82 millionP/E RatioN/ADividend YieldN/ABeta3.9 ProfileChartEarningsHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Cotinga Pharmaceuticals Inc., a biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, a clinical stage oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. was founded in 1999 and is based in Boston, Massachusetts. Receive COTQF News and Ratings via Email Sign-up to receive the latest news and ratings for COTQF and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:COTQF Previous Symbol CUSIPN/A CIKN/A Webwww.cotingapharma.com Phone519-858-5157Debt Debt-to-Equity RatioN/A Current Ratio0.17 Quick Ratio0.17Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.07) per share Price / Book-1.18Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-3,820,000.00 Net MarginsN/A Return on EquityN/A Return on Assets-201.46%Miscellaneous EmployeesN/A Outstanding Shares21,990,000Market Cap$1.82 million Next Earnings Date8/27/2019 (Estimated) OptionableNot Optionable Cotinga Pharmaceuticals (OTCMKTS:COTQF) Frequently Asked Questions What is Cotinga Pharmaceuticals' stock symbol? Cotinga Pharmaceuticals trades on the OTCMKTS under the ticker symbol "COTQF." How were Cotinga Pharmaceuticals' earnings last quarter? Cotinga Pharmaceuticals Inc (OTCMKTS:COTQF) posted its earnings results on Monday, April, 1st. The company reported ($0.01) earnings per share for the quarter. View Cotinga Pharmaceuticals' Earnings History. When is Cotinga Pharmaceuticals' next earnings date? Cotinga Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, August 27th 2019. View Earnings Estimates for Cotinga Pharmaceuticals. Has Cotinga Pharmaceuticals been receiving favorable news coverage? Media stories about COTQF stock have been trending somewhat positive on Sunday, InfoTrie reports. InfoTrie ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cotinga Pharmaceuticals earned a news impact score of 1.9 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term. Who are some of Cotinga Pharmaceuticals' key competitors? Some companies that are related to Cotinga Pharmaceuticals include Achaogen (AKAO), Endonovo Therapeutics (ENDV), Praxsyn (PXYN), DelMar Pharmaceuticals (DMPI), Auris Medical (EARS), Achaogen (AKAOQ), IntelliPharmaCeutics Intl (IPCI), Stellar Biotechnologies (SBOT), Integrated BioPharma (INBP), Innovus Pharmaceuticals (INNV), Wellness Center USA (WCUI), iCo Therapeutics (ICOTF), Uluru (ULUR), Bioblast Pharma (ORPN) and Innovus Pharmaceuticals (INNVD). What other stocks do shareholders of Cotinga Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cotinga Pharmaceuticals investors own include Choom (CHOOF), HighPoint Resources (HPR), Trillium Therapeutics (TRIL), SCYNEXIS (SCYX), Rigel Pharmaceuticals (RIGL), Novavax (NVAX), Nabriva Therapeutics (NBRV), Idera Pharmaceuticals (IDRA), Flex Pharma (FLKS) and ADMA Biologics (ADMA). Who are Cotinga Pharmaceuticals' key executives? Cotinga Pharmaceuticals' management team includes the folowing people: Ms. Alison D. Silva, CEO, Pres & DirectorDr. Richard T. Ho, Chief Scientific Officer (Age 56)Mr. Victor Hugo, Chief Financial Officer (Age 50)Ms. Debi Sanderson MBA, Director of Resourcing & OperationsMr. Paul Papi, VP of Investor Relations How do I buy shares of Cotinga Pharmaceuticals? Shares of COTQF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Cotinga Pharmaceuticals' stock price today? One share of COTQF stock can currently be purchased for approximately $0.0829. How big of a company is Cotinga Pharmaceuticals? Cotinga Pharmaceuticals has a market capitalization of $1.82 million. What is Cotinga Pharmaceuticals' official website? The official website for Cotinga Pharmaceuticals is http://www.cotingapharma.com. How can I contact Cotinga Pharmaceuticals? Cotinga Pharmaceuticals' mailing address is 127 Main Street, Boston MA, 02129. The company can be reached via phone at 519-858-5157 or via email at [email protected] MarketBeat Community Rating for Cotinga Pharmaceuticals (OTCMKTS COTQF)Community Ranking: 1.9 out of 5 ()Outperform Votes: 67 (Vote Outperform)Underperform Votes: 106 (Vote Underperform)Total Votes: 173MarketBeat's community ratings are surveys of what our community members think about Cotinga Pharmaceuticals and other stocks. Vote "Outperform" if you believe COTQF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe COTQF will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/19/2019 by MarketBeat.com StaffFeatured Article: Stock Symbol Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.